Physician profile
Kelley Meisner
NPI 1184295032
$2,367.75
in general payments reported to CMS, 2019-2025
27 companies · $625 in 2025
The $625 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33.51 · 2022: $559 · 2023: $497 · 2024: $654 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,775.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $384.88 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $323.91 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $249.48 | 2023-2025 | Farxiga |
| Amgen INC. | $202.08 | 2021-2025 | Evenity, Prolia, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.12 | 2022-2025 | Jardiance, Ofev |
| Pfizer INC. | $172.61 | 2023-2025 | |
| Exact Sciences Corporation | $129.83 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $106.40 | 2022-2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $71.47 | 2025 | Rexulti |
| Abbvie INC. | $70.42 | 2022-2023 | |
| Corium, LLC | $55.45 | 2022-2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $49.01 | 2022-2024 | Spravato |
| Boston Scientific Corporation | $45.10 | 2022-2024 | Watchman Access System |
| Merck Sharp & Dohme LLC | $34.19 | 2022-2023 | Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.67 | 2024-2025 | Xifaxan |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $28.84 | 2025 | Inspire |
| Abbott Laboratories | $25.76 | 2025 | Freestyle Libre 3 |
| Medtronic, INC. | $25.14 | 2024 | Venaseal |
| Acadia Pharmaceuticals INC | $24.41 | 2025 | Daybue |
| Glaxosmithkline, LLC. | $22.03 | 2024 | Shingrix, Arexvy |
| Astellas Pharma US INC | $21.55 | 2023 | Veozah |
| Corcept Therapeutics | $20.49 | 2023 | Korlym |
| Philips North America LLC | $20.24 | 2024 | (Ck7) Extended Holter |
| Impel Pharmaceuticals INC. | $20.12 | 2023 | Trudhesa |
| Lucid Diagnostics INC. | $17.60 | 2023 | |
| Phathom Pharmaceuticals, INC. | $14.18 | 2024 | Voquezna |
| Evoke Pharma, INC. | $12.77 | 2023 | Gimoti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelley Meisner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.